Skip to main content

Table 3 The major outcomes of clinical study on laparoscopic metabolic surgery for T2DM with BMI < 35 kg/m2 in Asia

From: Laparoscopic metabolic surgery for the treatment of type 2 diabetes in Asia: a scoping review and evidence-based analysis

Author/Year

Comorbidity

M

Diabetes remission rate

R/C

Major outcomes

Major Complications

Follow-up

Du 2016 [23]

Hypertension, Dyslipidemia

Hyperuricemia

Sleep apnea

0

LRYGB/LSG: 75%/78.9% at 1-year; 57.4% /52.9% at 3-year.

0

BMI, FPG, 2 h-PG, HbA1C, FCP, 2 h-CP, FINS, HOMA-IR

one Incomplete intestinal obstruction, one mild upper gastrointestinal bleeding

All completed 1 year follow-up, 3 were lost at 2 years, 2 lost at 3 years.

Di 2016 [24]

Hypertension, hyperlipidemia

0

74.2% (49/66) at 1-year; 57.6% (38/66) at 3-year

0

BMI, FPG, 2 hPG, HbA1C, FCP, FINS, HOMA-IR

No state

All completed 3 years follow-up

Gong 2016 [25]

Hypertriglyceridemia, Hypertension, Retinopathy

Peripheral neuropathy

0

93.5% (29/31) at 6-month

0

BMI, FPG, HbA1c, CP, FINS, GLP-1

No severe complications

All completed at 1, 3 and 6 months follow-up

Kular 2016 [26]

No state

0

1, 2, 5 and 7 years were 81.8% (18/22), 78.9% (30/38),70.3% (57/81) and 68.5% (74/108)

0

BMI, waist, HbA1c, EWL, mean weight

excessive postoperative suture line bleeding with shock, anastomotic ulceration, anemia, low albumin, bile reflux, excess weight loss

Only 16%(128) of patients lost to follow0up after 7 years

Li 2016 [27]

No state

0

59.6% (34/57) at 1-year

0

FPG, 2hPBG, HbA1C, BMI, 1 h C-P

one early hemorrhage

All at 1 year follow-up

Yang 2015 [28]

Hypertension

0

SG/RYGB: 78.6% (22/32)/ 85.2% (23/32) at 3-year

0

HbA1c, FBG, CP, BMI

Two gastroesophageal reflux, a anemia

55 patient completed 3 years follow-up

Yi 2015 [29]

No state

0

LRYGB/LRYGBS: 30% (9/30)/47% (14/30)

0

BMI, HOMA-IR, HbA1c, FPG, FCP, 2hCP

10 marginal ulcers, two gastrointestinal hemorrhage

All at 1 year follow-up

Kim 2014 [30]

No state

0

53%, 63%, 90% at 1, 2 and 3 year

1a

BMI, HbA1c, Fasting glucose, 2 h glucose, CP, Insulin, HOMA-IR

Postoperative bleeding, outflow stasis, infected fluid collection, leakage

144 at 1 year; 116 at 2 year, 51 at 3 year

Shrestha 2013 [31]

No state

0

A significant decrease in the levels of FPG, 2 h PG, HbA1c, and TG

0

BMI, HbA1c, FPG, 2hPG, FINS, HOMA-IR

No state

All at 3 month follow-up

Lakdawala 2013 [32]

Hypertension, dyslipidemia, hyperuricemia, gastroesophageal reflux disease, sleep apnea, joint pain

0

96.2% (50/52) at 1 year and 5 year

0

Average blood glucose, FINS, postprandial serum insulin, FCP, HbA1c

one seromas and one nausea, no major complication

4d, 1,3,6, months, 1, 2, 3, 4, 5 years

Wu 2013 [33]

No state

0

75% at 2 months, 83.3% at 4 months

0

BMI, FPG, 2hPG, HbA1c

two vomiting and diarrhea, two gastric fistula and infection

All at 2 months, 6 at 4 months.

Zhu 2012 [34]

Chronic gastritis, fatty liver, hypertension, hypertriglyceridemia, diabetic retinopathy, diabetic nephropathy

0

Significant reduction in Glycosylated hemoglobin, diabetes was completely resolved in 9 cases

0

BMI, Waist-hip ratio, FPG, 30 m PG, 2 h PG, HbA1C

No major complication

All at 12 months follow-up

Huang 2011 [35]

Hyperlipidemia, hypertension, steatohepatitis, gouty arthritis

0

90.9% (20/22) at 12 months.

0

BMI, Glucose, HbA1, ctriglyceride

No state

All at 12 months follow-up

Lee 2011 [36]

No state

0

0%,11%, 37%, 53%, 57%, and 55% patients in 1, 4, 12, 26, and 52 weeks and 2 years

0

BMI, Glucose, insulin, HbA1c, HOMA, Glucose, Insulin, Insulinogenic index

seven minor complications, no major complication

62 at 1,4 week, 45 at 12 week, 40 at 26 weeks, 30 at 52 weeks, 20 at 2 years.

Shah 2010 [37]

Hypertension, dyslipidemia

0

80% (12/15)at 3 months

0

BMI, Waist circumference, Fasting blood glucose, HbA1c

No major complication

All at 6, 9 months

Lee 2008 [38]

2 comorbidity

0

76.5% (34/44) at 1 year

0

BMI, glucose, T-chole, Triglyceride, insulin, CP, HbA1c

No major complication

At 1 year

  1. M mortality, R/C Reoperation/conversion to open, BMI Body mass index, FPG fasting plasma glucose, PG plasma glucose, HbA1C glycated hemoglobin, FCP fasting C peptide, CP c-peptide, FINS Fasting insulin, HOMA-IR homeostatic model of assessment-insulin resistance, GLR-1 glucagon-like peptide-1, EWL excess weight loss, PBG postprandial blood glucose
  2. aconversion to open surgery